Immuno-oncology therapy developer Century Therapeutics has emerged from stealth, having been established by Versant Ventures to advance Stanford and Harvard research.
US-based immuno-oncology drug developer Century Therapeutics emerged from stealth yesterday with $250m in funding to commercialise research from Harvard University’s Medical School and Stanford University School of Medicine.
Leaps by Bayer, an investment vehicle for pharmaceuticals and chemicals producer Bayer, invested $215m to lead the round, and was joined by Fujifilm Cellular Dynamics (FCDI), a biotech-focused subsidiary of imaging technology producer Fujifilm.
Venture capital firm Versant Ventures also took part in the round, having established Century Therapeutics in…
